Skip over navigation
The Hospital
Research
Support Us
Ottawa Hospital Research Institute
Home
Français
Directions & Maps
Contact Us
About Us
Vision and Strategic Directions
Board Chair and CEO Message
Leadership Team
Annual Reports
Facilities
Research Data Management
Equity, Diversity and Inclusion
Wellness
Our Research
Priorities, Programs and Diseases
Researcher Profiles
National Research Networks
Scientific Publications
Research Awards
Technology Transfer
Industry Sponsored Research
Responsible Innovation
For Students & Fellows
News & Events
Newsroom
Seminars & Events
Career Opportunities
For Patients
News & Events
Home
>
News & Events
>
Newsroom
Bookmark or Share
Display Options
Display Options
+
Increase
/
-
Decrease
font size
High contrast version
Printer-friendly version
Newsroom
Seminars & Events
Newsroom
OHRI-led clinical trial demonstrates first evidence that new colorectal cancer drug saves lives
November 14, 2007
An OHRI-led clinical trial has provided the first evidence that a new class of drug can improve survival in colorectal cancer patients in whom all other therapies had failed. The drug, called cetuximab, is targeted against growth-promoting molecules on the surface of cancer cells. Patients who received the drug survived 23 per cent longer, with significant improvements in quality of life. The study included nearly 600 patients from Canada, Australia, New Zealand and Singapore and was funded by the National Cancer Institute of Canada, ImClone Systems and Bristol-Myers Squibb. It was led by medical oncologist Dr. Derek Jonker (affiliated with the OHRI, The Ottawa Hospital and the University of Ottawa) and published in the
New England Journal of Medicine
.
Links:
Ottawa Citizen story
Forbes story
New England Journal of Medicine paper